What Chemspace does

Chemspace is a privately held, founder-operated drug discovery platform founded in 2016 and headquartered in Monmouth Junction, New Jersey, with regional offices in Riga, Latvia and Kyiv, Ukraine. The company operates a global chemical e-procurement marketplace and integrated Discovery CRO serving pharmaceutical companies, biotechnology firms, and academic research institutions across the Americas, EMEA, and Asia-Pacific. Its core product, Freedom Space 5.0, is a virtual enumerated chemical space of 296 billion synthetically accessible compounds constructed from over 215,000 building blocks across 39 synthetic protocols, supplemented by Enamine's xREAL Space for access to trillions of make-on-demand compounds and a biologics catalog of 486,056 items.

The platform is differentiated by proprietary computational chemistry capabilities including V-SYNTHES hierarchical enumeration screening (4.4T-molecule scale), AL-accelerated molecular docking (10–100x brute-force speedup), DEL-ML-CS workflows combining DNA-encoded library screening with ML-based hit expansion, DiffDock generative diffusion models for blind docking, and 3D Atomic Property Fields/pharmacophore-based analog search. These capabilities are tightly integrated with synthesis (via Enamine), biology (via Bienta), and DEL libraries (via HitGen) to deliver a Design-Make-Test-Analyze cycle in 10–15 business days.

Chemspace generates revenue through three streams: per-transaction marketplace commissions on compound purchases, FTE/FFS-billed Discovery CRO services (hit identification through preclinical studies), and recurring Purchasing SaaS subscriptions offering Custom Platform, Punchout Site, and Chemspace API integrations. Distribution is hybrid: direct enterprise field sales with regional Business Development Directors for the US and Europe, supplemented by channel partners (BioSolveIT, Alipheron, Pharmacelera, ASKCOS) embedding Freedom Space within third-party computational chemistry tools. Pricing is quote-based and not publicly disclosed. The company is bootstrapped with no disclosed institutional funding, and is led by CEO Olga Tarkhanova, PhD, and COO Olena Strapak.

Name

Chemspace

Legal name

SIA "Chemspace"

Website

https://chem-space.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Chemspace is a bootstrapped, founder-led drug discovery platform offering an integrated marketplace of ultra-large chemical spaces (296B+ compounds), AI/ML-driven Discovery CRO services, and compound procurement SaaS for pharmaceutical, biotechnology, and academic research customers worldwide.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Computer Systems Design and Related Services (54151), Custom Computer Programming Services (541511), Medicinal and Botanical Manufacturing (325411)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Prepackaged Software (7372), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Chemical e-procurement
• Drug discovery CRO
• Virtual screening services
• Molecular docking
• Chemical space exploration

Headquarters

HQ city

Monmouth Junction

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Marketplace / Catalog Sales: Chemspace operates a chemical e-procurement marketplace where researchers search, select, and purchase compounds from catalog collections (in-stock and make-on-demand). Revenue is generated through per-transaction fees on compound purchases across multiple supplier catalogs.
2. Discovery CRO Professional Services: End-to-end drug discovery services including hit identification, molecular docking, fragment-based drug discovery, DEL-ML workflows, virtual screening, ML-based services, and integrated drug discovery from target analysis through preclinical studies. Billed on FTE or FFS (full-time equivalent or fee-for-service) models.
3. Purchasing SaaS: Subscription-based software-as-a-service offering for compound procurement workflow automation. Includes custom platform integrations, punchout sites, and Chemspace API, enabling clients to streamline procurement across multiple suppliers.

Pricing tiers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels5 records

Core offering

Chemspace operates a global chemical e-procurement marketplace aggregating catalogs from multiple suppliers (Enamine, UORSY, FCH Group, AmBeed, BLDpharm and others) and provides access to ultra-large enumerated chemical spaces (Freedom Space 5.0 with 296 billion compounds and Enamine xREAL Space with trillions of make-on-demand compounds). Beyond procurement, it delivers integrated Discovery CRO services spanning hit identification, molecular docking (classical, AL-accelerated, V-SYNTHES), fragment-based drug discovery, DEL-ML workflows, virtual screening, ML-based services, and end-to-end drug discovery from target analysis through preclinical studies. It also offers a Purchasing SaaS for procurement workflow automation via Custom Platform, Punchout Site, and Chemspace API.

Product overview

Chemspace is a drug discovery platform offering integrated services spanning chemical space exploration and compound procurement. The core offering is Freedom Space 5.0, an ultra-large virtual chemical space of 296 billion compounds, supplemented by small molecule and biologics search catalogs (486,056 items). The Discovery CRO division provides specialized services including DNA-encoded library screening (DEL-ML-CS), molecular docking (classical, AL-accelerated, and V-SYNTHES for ultra-large spaces), fragment-based drug discovery, virtual screening, 3D shape/ pharmacophore search, molecular dynamics, and ML-based services. The Purchasing SaaS module enables integrated procurement through custom platforms, punchout sites, and API integration. All services are supported by partnerships with Enamine (chemical synthesis) and Bienta (biology services).

Differentiator

Problem solved

Functional benefit

Products and services

• Freedom Space 5.0 Ultra-large virtual chemical space of 296 billion chemically diverse, synthesizable compounds built from 215,000+ building blocks across 39 synthetic protocols; enables virtual screening, hit identification, and compound ordering with 5-6 week delivery.
• Small Molecules Search Search engine for small molecules across extensive supplier catalogs, allowing queries by SMILES, name, CAS, MFCD, ID, or InChI Key.
• Biologics Catalog Searchable catalog of 486,056 biologics including proteins, antibodies, kits, and related products for bio-related research projects.
• Compound Sets Pre-selected screening compound sets for HTS, fragment-based drug discovery, DNA-encoded chemical libraries, and PROTAC technologies, including cherry-picking and pre-plated solutions.
• AI-Supported Focused Libraries ML-generated focused compound libraries designed for specific targets or research requirements.
• Discovery CRO Services Comprehensive drug discovery contract research services covering hit finding, research informatics, and integrated drug discovery from target analysis to preclinical studies.
• DEL-ML-CS DNA-Encoded Library technology combined with ML-supervised data processing for screening up to 3B compounds in a single tube, with ML-based hit expansion into large chemical spaces; allows testing of up to 200 molecules for the price of 20 custom syntheses.
• Molecular Docking Services Structure-based drug design service for protein-ligand binding prediction, offering classical docking (4.7M-7.9M compounds), AL-accelerated docking (up to 1B subsets), and V-SYNTHES approach (up to 4.4T molecules).
• V-SYNTHES Approach Virtual synthon hierarchical enumeration screening approach powered by MolSoft ICM-Pro for ultra-large chemical spaces (up to 4.4T molecules), enabling giga-scale virtual screening without full enumeration via minimal enumeration library docking.
• Fragment-Based Drug Discovery FBDD service identifying fragment hits complying with Rule of 3, with fragment growing within Enamine REAL and Freedom Spaces; delivers 100-500 most promising compounds selected after docking and hit validation.
• Virtual Screening Structure-based and ligand-based virtual screening combining SBVS (molecular docking, 4D ensemble docking, RIDGE, pharmacophore modeling) and LBVS (pharmacophore, QSAR, shape-based screening) approaches, with reported success rates over 80%.
• 3D Shape and Pharmacophore-Based Analog Search 3D analog search platform using Atomic Property Fields and pharmacophore-based modeling for scaffold hopping, lead optimization, and exploration of underrepresented chemical space.
• Molecular Dynamics Simulation MD simulation services for proteins and protein-ligand complexes including simple protein MD, steered MD, and absolute/relative binding free energy calculations.
• Machine Learning-based Services ML services including ML-driven hit expansion, ML-supported data analysis, DiffDock blind docking, physicochemical property prediction (logP, logD, solubility), and active learning for property optimization.
• Integrated Drug Discovery End-to-end integrated drug discovery service utilizing Design-Make-Test-Analyze cycle completed within 10-15 business days, with collaboration between medicinal chemistry, synthetic chemistry (Enamine), computational chemistry, and molecular biology (Bienta).
• Purchasing SaaS Software-as-a-Service procurement platform with three integration options: Custom Platform, Punchout Site, and Chemspace API for simplifying compound purchasing workflows across multiple suppliers.
• SDS/CoA Service Safety Data Sheet preparation in 6 languages and Certificate of Analysis download service for purchased compounds, with regulatory information resources.

Quantifiable outcome

• Virtual screening success rate over 80% in custom workflows
• +4 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability11 records

Feature8 records

Partnerships

16 partnerships are on record, tiered core, flagship, strategic and minor.

• PharmaceleracoreTechnology or Integration · 3 March 2026Chemspace Freedom Space 5.0 is integrated with Pharmacelera's exaScreen platform for 3D ultra-large virtual screening. The combined offering provides access to 296 billion chemically diverse, synthesizable compounds using Pharmacelera's 3D Quantum-Mechanics and Machine Learning algorithms for drug discovery research.
• EnamineflagshipStrategic or Co-development Partner · 25 February 2026Enamine is a contract research organization with 4.7 million screening compounds and 350,000 building blocks in stock, having spent 35 years charting synthetically accessible chemical space. Chemspace integrated Enamine's xREAL Space into its platform, giving researchers worldwide access to search and purchase trillions of make-on-demand chemical compounds through a single online source. Enamine's synthesis capabilities power Chemspace's rapid compound delivery (4–6 weeks).
• MolSoftcoreTechnology or IntegrationMolSoft's ICM-Pro software is used for classical molecular docking, V-SYNTHES virtual screening approach, and 3D pharmacophore modeling across Chemspace's discovery services. ICM-Pro has demonstrated strong performance in blinded modeling competitions and docking challenges.
• BioSolveITcoreTechnology or IntegrationFreedom Space 5.0 (296 billion compounds) is available within BioSolveIT's chemical space navigation tools, supporting multiple complementary approaches including ligand-based similarity, pharmacophore search, substructure matching, and structure-based virtual screening.
• AlipheroncoreTechnology or IntegrationFreedom Space 4.0 (142 billion molecules) is searchable through Alipheron's Hyperspace and Pharos-3D tools, enabling researchers using Alipheron's platform to access Chemspace's chemical space directly.
• ASKCOScoreTechnology or IntegrationASKCOS is an open-source computer-aided synthesis planning platform. Chemspace partnered with ASKCOS to include its building blocks directly in ASKCOS workflows, enabling seamless transition from synthesis pathway design to compound purchase through one integrated platform.
• BientacoreStrategic or Co-development PartnerBienta provides biology services as part of Chemspace's integrated drug discovery offering. The collaboration enables Chemspace to cover both computational chemistry and wet biology validation steps, from target analysis through preclinical studies.
• PharmAI GmbHstrategicStrategic or Co-development PartnerChemspace, Enamine, and PharmAI GmbH Discovery (PAID) entered a transformative collaboration to accelerate advancement of theranostics through AI-driven drug discovery with emphasis on cancer diagnosis and therapy.
• Innovative Health Initiative (IHI) — LIGAND-AI ProjectflagshipStrategic or Co-development PartnerEnamine and Chemspace joined the IHI Project LIGAND-AI, a multinational public-private initiative to advance AI-driven drug discovery by generating large datasets of protein-ligand interactions. The project involves academic, industry, and technology partners across nine countries with a budget exceeding €60 million over five years, fostering open science and accelerating early-stage drug discovery workflows.
• HitGencoreTechnology or IntegrationHitGen provides DNA-encoded library options including OpenDEL Small Molecules (3.8B compounds), OpenDEL Macrocycles (200M), AlphaMa DEL kit (1B), and Covalent DEL kit (9M). These DEL options are integrated into Chemspace's DEL-ML-CS discovery workflow.
• FCH GroupcoreChannel Partner/ Reseller/ DistributorFCH Group is listed as a Chemspace Partner with advanced features and additional privileges under the Partnership Agreement. FCH Group is also listed as a supplier under Distribution Agreement.
• UORSY (UkrOrgSyntez Ltd)coreChannel Partner/ Reseller/ DistributorUORSY (UkrOrgSyntez Ltd) is listed as a Chemspace Partner under Partnership Agreement with advanced features and additional privileges, and as a supplier under Distribution Agreement.
• AmBeed GmbHminorChannel Partner/ Reseller/ DistributorAmBeed GmbH catalog of in-stock compounds mapped to warehouse locations in Germany and China is available on the Chemspace platform, enabling India dropship fulfillment.
• BLDpharmminorChannel Partner/ Reseller/ DistributorChemspace expanded its catalog with 65,000 compounds from BLDpharm India warehouse, now available for search and direct purchasing with India dropship capability.
• Enamine LtdcoreChannel Partner/ Reseller/ DistributorEnamine Ltd is listed as a Chemspace Partner with advanced features and additional privileges under the Partnership Agreement. Enamine's extensive compound library and synthesis capabilities are central to Chemspace's catalog and Discovery CRO services.
• AbcamflagshipStrategic or Co-development PartnerAbcam joined the IHI LIGAND-AI project alongside Chemspace and Enamine, contributing recombinant protein engineering and production capabilities to generate high-quality binding datasets for AI model development targeting rare, neurological, and oncological conditions.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Enamine: Enamine is both Chemspace's flagship synthesis partner and a direct competitor in ultra-large enumerated chemical space (REAL/xREAL Space). Both companies supply make-on-demand compounds and screen diverse building-block libraries to pharma/biotech customers.
• eMolecules: eMolecules operates a chemical search and procurement marketplace similar to Chemspace's small-molecule and biologics search business, aggregating catalog compounds from multiple suppliers for pharma and academic researchers.
• MolPort: MolPort is a chemical marketplace and sourcing platform serving pharma/biotech with multi-supplier compound search and procurement, directly comparable to Chemspace's catalog marketplace offering.
• Schrödinger: Schrödinger provides computational chemistry, molecular docking, FEP+, virtual screening, and ML-based drug discovery software/services to pharma — overlapping directly with Chemspace's Discovery CRO and ML services line.
• Atomwise: Atomwise applies AI/ML to ultra-large virtual libraries for hit identification and optimization, comparable to Chemspace's V-SYNTHES, AL-accelerated docking, and DEL-ML-CS workflows targeting early drug discovery.
• ChemBridge Corporation: ChemBridge supplies screening compound libraries, building blocks, and custom synthesis services to pharma/biotech — directly overlapping with Chemspace's catalog marketplace, compound sets, and custom synthesis offerings.
• Mcule: Mcule operates a chemical marketplace and in silico drug discovery platform offering purchasable compound databases, virtual screening, and chemical space exploration — directly comparable to Chemspace's Freedom Space and marketplace.
• Key Organics / Bionet: Key Organics supplies screening compounds, building blocks, and custom synthesis to pharma and biotech — directly comparable to Chemspace's catalog and custom synthesis business lines.

Broad incumbents

• WuXi AppTec: WuXi AppTec is a global CRO offering discovery chemistry, computational services, and integrated drug discovery — a broader incumbent that competes with Chemspace's Discovery CRO and integrated drug discovery offering.
• Charles River Laboratories: Charles River Laboratories offers early-stage drug discovery services including compound sourcing, computational chemistry, and integrated discovery — a broad incumbent competing with Chemspace's Discovery CRO line.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/chemspace
• Xx.com/chem_space
• Facebookfacebook.com/chemspace

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chemspace